

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number
WO 01/52649 A1

(51) International Patent Classification⁷: A01N 1/02,
C12N 5/00, 5/02, 7/00, 15/63, 15/86, C12P 21/04, 21/06

69 Peter Courtis Circle, Stanford, CA 94305 (US). WEISS-
MAN, Irving, L.; 4147 Jefferson Avenue, Redwood City,
CA 94061 (US).

(21) International Application Number: PCT/US01/01459

(22) International Filing Date: 17 January 2001 (17.01.2001)

(74) Agent: SHERWOOD, Pamela, J.; Bozicevic, Field &
Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park,
CA 94025 (US).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AU, CA.

(30) Priority Data:
60/176,786 18 January 2000 (18.01.2000) US

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(71) Applicant: THE BOARD OF TRUSTEES OF THE LE-
LAND STANFORD JUNIOR UNIVERSITY [US/US];
Suite 350, 900 Welch Road, Palo Alto, CA 94304 (US).

Published:
— with international search report

(72) Inventors: REYA, Tannishtha; 777 W. Middlefield Road
#200, Mountain View, CA 94043 (US). NUSSE, Roeland;

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



VO 01/52649 A1

(54) Title: EXPANSION OF STEM AND PROGENITOR CELLS BY BETA-CATENIN

(57) Abstract: Mammalian progenitor or stem cells are expanded *in vitro* by increasing the levels of β -catenin in the cell. The ex-
panded cells substantially maintain their original phenotype including the ability to give rise to multiple types of differentiated cells.
The intracellular levels of β -catenin may be manipulated by providing exogenous β -catenin protein to the cell, or by introduction
into the cell of a genetic construct encoding β -catenin. The β -catenin may be a wild-type or stabilized mutant form of the protein.

EXPANSION OF STEM AND PROGENITOR CELLS BY BETA-CATENIN

INTRODUCTION

Beta-catenin is a pivotal player in the signaling pathway initiated by Wnt proteins, which are mediators of several developmental processes. Beta-catenin activity is controlled by a large number of binding partners that affect the stability and the localization of beta-catenin, and it is thereby able to participate in such varying processes as gene expression and cell adhesion. Activating mutations in beta-catenin and in components regulating its stability have been found to contribute to upregulation of cell proliferation.

The β -catenin protein becomes stabilized in response to Wnt/Wg, moves to the nucleus and forms complexes with the LEF1/TCF transcription factors to regulate gene expression. The level of cytosolic β -catenin is determined by its interaction with a number of proteins including those in a multiprotein complex of Axin, GSK-3 β , APC and other proteins. The mechanism by which the Wnt signal is transmitted to this complex is unclear but it involves interaction of Wnt with its receptors, which are members of Frizzled family of seven transmembrane proteins. The stabilization of β -catenin stimulates the expression of genes including c-myc, c-jun, fra-1, and cyclin D1. This pathway is negatively regulated by Axin.

Beta-catenin is also an adherens junction protein. Adherens junctions are critical for the establishment and maintenance of epithelial layers, such as those lining organ surfaces. AJs mediate adhesion between cells, communicate a signal that neighboring cells are present, and anchor the actin cytoskeleton. In serving these roles, AJs regulate normal cell growth and behavior. At several stages of embryogenesis, wound healing, and tumor cell metastasis, cells form and leave epithelia. This process, which involves the disruption and reestablishment of epithelial cell-cell contacts, may be regulated by the disassembly and assembly of AJs. AJs may also function in the transmission of the 'contact inhibition' signal, which instructs cells to stop dividing once an epithelial sheet is complete.

For many purposes, there is an interest in being able to expand stem and progenitor cells in culture. However, it is not simply a matter of maintaining cell viability for the stem cells, but also of ensuring that the stem cells increase in numbers without losing their distinctive phenotype. Current protocols for the *in vitro* culture of hematopoietic stem cells generally require one or a cocktail of cytokines, such as c-kit ligand (stem cell growth factor), flt-3, thrombopoietin, IL-6, etc. While a substantial increase in cell number can be obtained with such cultures, they do not provide for expanded number of cells that retain a capacity for long term repopulation of all hematopoietic lineages. See Domen and Weissman (1999) Mol Med Today 5(5):201-8; or Ziegler and Kanz (1998) Curr Opin Hematol 5(6):434-40.

Stem cells have also been grown in co-culture with stromal cells. However, it is particularly desirable to expand stem cells in a culture of known composition, rather than relying upon the presence of other cells for their maintenance.

There continues to be a strong demand for improvements in the *in vitro* culture of stem cells and progenitor cells. The present invention addresses this need.

SUMMARY OF THE INVENTION

Methods are provided for the expansion of progenitor or stem cells *in vitro*, whereby the cells retain their pluripotential phenotype after expansion. The intracellular level of β -catenin is increased in the cells in culture, either by providing exogenous β -catenin protein to the cell, or by introduction into the cell of a genetic construct encoding β -catenin. The β -catenin may be a wild type protein appropriate for the species from which the cells are derived, or preferably, a stabilized mutant form of the protein. The alteration in cellular levels of β -catenin provide for increased number of cells in cycle, and leads to cultures that containing proliferating cells that maintain an undifferentiated phenotype *in vitro*. The expanded cell populations are useful as a source of stem cells, e.g. to reconstitute function in a host that is deficient in a particular cell lineage or lineages. In one embodiment of the invention, the target cells are hematopoietic stem cells, which may be used in transplantation to restore hematopoietic function to autologous or allogeneic recipients.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Activated beta-catenin retrovirus induces increased growth of stem cells. Stem cells infected with control or beta-catenin-GFP retrovirus were sorted and cultured on 96 well plates for two days in the presence or absence of steel factor, and cell numbers were counted at the end of the culture period.

Figure 2. Stem cells infected with beta-catenin retain many stem cell markers in long term culture. Beta-catenin infected stem cell spheres were harvested from long term cultures at 5 weeks, trypsinized and allowed to express their surface proteins for 12 hours. Subsequently they were harvested and stained with antibodies to Thy1.1, Sca1, c-kit, and lineage antigens (B220, Mac-1, Gr-1, Ter119, CD5, CD3, CD8/4).

Figure 3. Stem cells infected with beta-catenin have the ability to give rise to multiple lineages when transplanted. 100,000 beta-catenin infected stem cells were harvested from long term cultures at 7 weeks, trypsinized and injected into lethally irradiated (950 Rads) allotype marked recipients along with 300,000 rescuing bone marrow cells from the host. Analysis of reconstitution along various lineages was carried out at 4 weeks after transplantation.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Mammalian progenitor or stem cells are expanded *in vitro* by increasing the levels of β -catenin in the cell. The intracellular levels of β -catenin may be manipulated by providing exogenous β -catenin protein to the cell, or by introduction into the cell of a genetic construct encoding β -catenin. The β -catenin may be a wild-type or stabilized mutant form of the protein. Preferably the long term cell culture medium substantially lacks stromal cells and cytokines. Cultures that provide stem cell activity can be obtained for at least three weeks, frequently six weeks and can be eight weeks or more. The culture media that are employed are conventional media for the growth of mammalian cells, optionally in the absence of serum using only defined protein factors. In the absence of the β -catenin, the medium is inefficient at maintaining growth of the undifferentiated cells.

In the first few days of culture, the expansion of stem/progenitor cells is limited, usually the number of phenotypic stem/progenitor cells is maintained, or slightly increased. After 2 to 3 weeks in the subject culture conditions, there is a substantial proliferation of cells having the desired phenotype, where the number of cells having a functional stem/progenitor cell phenotype is expanded.

DEFINITIONS

It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines, animal species or genera, and reagents described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

As used herein the singular forms "a", "and", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and reference to "the culture" includes reference to one or more cultures and equivalents thereof known to those skilled in the art, and so forth. All technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs unless clearly indicated otherwise.

30

β -catenin: The term β -catenin, as used herein, is intended to refer to both wild-type and stabilized forms of the β -catenin protein, and to fusion proteins and derivatives thereof. Usually the protein will be of mammalian origin, although the protein from other species may find use. The protein is conserved between species, for example the human sequence is active in mouse cells. The sequences of many β -catenin proteins are publicly known. For convenience, the sequences of the human and mouse homologs of this protein are provided

35

in the sequence listing, as SEQ ID NO:1; and SEQ ID NO:2, respectively. In one embodiment of the invention, a stabilized form of beta-catenin is used.

5 The ubiquitin-dependent proteolysis system is involved in the regulation of beta-catenin turnover. Beta-catenin becomes stabilized when proteasome-mediated proteolysis is inhibited and this leads to the accumulation of multi-ubiquitinated forms of beta-catenin (Aberle et al. (1997) EMBO J 16(13):3797-804). Substitution of the serine residues in the glycogen synthase kinase 3 β (GSK3 β) phosphorylation consensus motif of beta-catenin inhibits ubiquitination and results in stabilization of the protein. Examples of stabilized β -catenins include those with the amino acid changes D32Y; D32G; S33F; S33Y; G34E; S37C;
10 S37F; T41I; S45Y; and deletion of AA 1-173. A number of publications describe stabilized β -catenin mutations. For example, see Morin et al. (1997) Science 275(5307):1787-90; Palacios et al. (1998) Cancer Res 58(7):1344-7; Muller et al. (1998) Genes Chromosomes Cancer 22(1):37-41; Miyoshi et al. (1998) Cancer Res 58(12):2524-7; Zurawel et al. (1998) Cancer Res. 58, 896-899; Voeller et al. (1998) Cancer Res. 58, 2520-2526; etc.

15 The sequence of the beta-catenin polypeptide may be altered in various ways known in the art to generate targeted changes in sequence. The polypeptide will usually be substantially similar to the sequences provided herein, i.e. will differ by at least one amino acid, and may differ by at least two but not more than about ten amino acids. Deletions may further include larger changes, such as deletions of a domain or exon, providing for active
20 peptide fragments of the protein. Other modifications of interest include tagging, e.g. with the FLAG system, HA, green fluorescent protein, etc. Such alterations may be used to alter properties of the protein, by affecting the stability, specificity, etc. The protein may be joined to a wide variety of other oligopeptides or proteins for a variety of purposes, particular for facilitating transport across membranes.

25 Techniques for *in vitro* mutagenesis of cloned genes are known. Examples of protocols for scanning mutations may be found in Gustin et al., Biotechniques 14:22 (1993); Barany, Gene 37:111-23 (1985); Colicelli et al., Mol Gen Genet 199:537-9 (1985); and Prentki et al., Gene 29:303-13 (1984). Methods for site specific mutagenesis can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, CSH Press 1989, pp. 15.3-
30 15.108; Weiner et al., Gene 126:35-41 (1993); Sayers et al., Biotechniques 13:592-6 (1992); Jones and Winistorfer, Biotechniques 12:528-30 (1992); Barton et al., Nucleic Acids Res 18:7349-55 (1990); Marotti and Tomich, Gene Anal Tech 6:67-70 (1989); and Zhu Anal Biochem 177:120-4 (1989).

35 *Expression construct:* In one embodiment of the invention, the beta-catenin is delivered to the targeted stem or progenitor cells by introduction of an exogenous nucleic acid expression vector into the cells. Many vectors useful for transferring exogenous genes

into target mammalian cells are available. The vectors may be episomal, e.g. plasmids, virus derived vectors such cytomegalovirus, adenovirus, etc., or may be integrated into the target cell genome, through homologous recombination or random integration, e.g. retrovirus derived vectors such MMLV, HIV-1, ALV, etc.

5 Retrovirus based vectors have been shown to be particularly useful when the target cells are hematopoietic stem cells. For example, see Baum *et al.* (1996) *J Hematother* 5(4):323-9; Schwarzenberger *et al.* (1996) *Blood* 87:472-478; Nolte *et al.* (1996) *P.N.A.S.* 93:2414-2419; and Maze *et al.* (1996) *P.N.A.S.* 93:206-210. Lentivirus vectors have also been described for use with hematopoietic stem cells, for example see Mochizuki *et al.*
10 (1998) *J Virol* 72(11):8873-83. The use of adenovirus based vectors with hematopoietic cells has also been published, see Ogniben and Haas (1998) Recent Results Cancer Res 144:86-92.

Various techniques known in the art may be used to transfect the target cells, e.g. electroporation, calcium precipitated DNA, fusion, transfection, lipofection and the like. The
15 particular manner in which the DNA is introduced is not critical to the practice of the invention.

Combinations of retroviruses and an appropriate packaging line may be used, where the capsid proteins will be functional for infecting the target cells. Usually, the cells and virus will be incubated for at least about 24 hours in the culture medium. Commonly used
20 retroviral vectors are "defective", i.e. unable to produce viral proteins required for productive infection. Replication of the vector requires growth in the packaging cell line.

The host cell specificity of the retrovirus is determined by the envelope protein, env (p120). The envelope protein is provided by the packaging cell line. Envelope proteins are of at least three types, ecotropic, amphotropic and xenotropic. Retroviruses packaged with
25 ecotropic envelope protein, e.g. MMLV, are capable of infecting most murine and rat cell types. Ecotropic packaging cell lines include BOSC23 (Pear *et al.* (1993) *P.N.A.S.* 90:8392-8396). Retroviruses bearing amphotropic envelope protein, e.g. 4070A (Danos *et al.*, *supra.*), are capable of infecting most mammalian cell types, including human, dog and mouse. Amphotropic packaging cell lines include PA12 (Miller *et al.* (1985) *Mol. Cell. Biol.* 5:431-
30 437); PA317 (Miller *et al.* (1986) *Mol. Cell. Biol.* 6:2895-2902) GRIP (Danos *et al.* (1988) *PNAS* 85:6460-6464). Retroviruses packaged with xenotropic envelope protein, e.g. AKR env, are capable of infecting most mammalian cell types, except murine cells.

The sequences at the 5' and 3' termini of the retrovirus are long terminal repeats (LTR). A number of LTR sequences are known in the art and may be used, including the
35 MMLV-LTR; HIV-LTR; AKR-LTR; FIV-LTR; ALV-LTR; etc. Specific sequences may be accessed through public databases. Various modifications of the native LTR sequences are also known. The 5' LTR acts as a strong promoter, driving transcription of the β -catenin

gene after integration into a target cell genome. For some uses, however, it is desirable to have a regulatable promoter driving expression. Where such a promoter is included, the promoter function of the LTR will be inactivated. This is accomplished by a deletion of the U3 region in the 3' LTR, including the enhancer repeats and promoter, that is sufficient to inactivate the promoter function. After integration into a target cell genome, there is a rearrangement of the 5' and 3' LTR, resulting in a transcriptionally defective provirus, termed a "self-inactivating vector".

Suitable inducible promoters are activated in a desired target cell type, either the transfected cell, or progeny thereof. By transcriptional activation, it is intended that transcription will be increased above basal levels in the target cell by at least about 100 fold, more usually by at least about 1000 fold. Various promoters are known that are induced in hematopoietic cell types, e.g. IL-2 promoter in T cells, immunoglobulin promoter in B cells, etc.

Preferred genetic constructs are those that can be removed from the target cells after expansion. This can be accomplished by the use of a transient vector system, or by including a heterologous recombination site that flanks the beta-catenin coding sequence. In this manner, after expansion the construct can be removed prior to use of the expanded cell population. Preferably a detectable marker, e.g. green fluorescent protein, luciferase, cell surface proteins suitable for antibody selection methods, etc. is included in the expression vector, such that after deletion of the construct the cells can be readily isolated that lack the exogenous beta-catenin.

The term "heterologous recombination site" is meant to encompass any introduced genetic sequence that facilitates site-specific recombination. In general, such sites facilitate recombination by interaction of a specific enzyme with two such sites. Exemplary heterologous recombination sites include, but are not necessarily limited to, *lox* sequences with recombination mediated by Cre enzyme; *frt* sequences (Golic et al. (1989) *Cell* 59:499-509; O'Gorman et al. (1991) *Science* 251:1351-5; recombination mediated by the FLP recombinase), the recognition sequences for the pSR1 recombinase of *Zygosaccharomyces rouxii* (Matsuzaki et al. (1990) *J. Bacteriol.* 172:610-8), and the like.

Sequences encoding *lox* sites are of particular interest for use in the present invention. A *lox* site is a nucleotide sequence at which the gene product of the *cre* gene, referred to herein as "Cre," catalyzes site-specific recombination. A particularly preferred *lox* site is a *loxP* site. The sequence of *loxP*, which is 34 bp in length, is known and can be produced synthetically or can be isolated from bacteriophage P1 by methods known in the art (see, e.g. Hoess et al. (1982) *Proc. Natl. Acad. Sci. USA* 79:3398). The *loxP* site is composed of two 13 bp inverted repeats separated by an 8 bp spacer region. Other suitable

lox sites include *loxB*, *loxL*, and *loxR*, which can be isolated from *E. coli* (Hoess et al. (1982) *Proc. Natl. Acad. Sci. USA* 22:3398).

In an alternative method, expression vectors that provide for the transient expression in mammalian cells may be used. In general, transient expression involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient short term expansion of cells, but do not affect the long term genotype of the cell.

Translocation modified β -catenin: In some cases it is desirable to provide exogenous β -catenin protein, rather than transducing the cells with an expression construct. The beta-catenin may be added to the culture medium at high levels. Preferably the beta-catenin is modified so as to increase its transport into the cells.

In one embodiment of the invention, tat protein is used to deliver beta-catenin. The preferred transport polypeptides are characterized by the presence of the tat basic region amino acid sequence (amino acids 49-57 of naturally-occurring tat protein); the absence of the tat cysteine-rich region amino acid sequence (amino acids 22-36 of naturally-occurring tat protein) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86 of naturally-occurring tat protein). Transport polypeptides are attached to beta-catenin by chemical cross-linking or by genetic fusion, where the beta-catenin moiety may be a wild-type or stabilized form. A unique terminal cysteine residue is a preferred means of chemical cross-linking.

Stem cell: The term stem cell is used herein to refer to a mammalian cell that has the ability both to self-renew, and to generate differentiated progeny (see Morrison *et al.* (1997) *Cell* 88:287-298). Generally, stem cells also have one or more of the following properties: an ability to undergo asynchronous, or symmetric replication, that is where the two daughter cells after division can have different phenotypes; extensive self-renewal capacity; capacity for existence in a mitotically quiescent form; and clonal regeneration of all the tissue in which they exist, for example the ability of hematopoietic stem cells to reconstitute all hematopoietic lineages. "Progenitor cells" differ from stem cells in that they typically do not have the extensive self-renewal capacity, and often can only regenerate a subset of the lineages in the tissue from which they derive, for example only lymphoid, or erythroid lineages in a hematopoietic setting.

Stem cells may be characterized by both the presence of markers associated with specific epitopes identified by antibodies and the absence of certain markers as identified by

the lack of binding of specific antibodies. Stem cells may also be identified by functional assays both *in vitro* and *in vivo*, particularly assays relating to the ability of stem cells to give rise to multiple differentiated progeny.

5 Stem cells of interest include hematopoietic stem cells and progenitor cells derived therefrom (U.S. Pat. No. 5,061,620); neural crest stem cells (see Morrison *et al.* (1999) Cell 96:737-749); embryonic stem cells; mesenchymal stem cells; mesodermal stem cells; *etc.*

Other hematopoietic "progenitor" cells of interest include cells dedicated to lymphoid lineages, e.g. immature T cell and B cell populations. The methods of the present invention are useful in expanding selected populations of these cells.

10 Purified populations of stem or progenitor cells may be used to initiate the cultures. For example, human hematopoietic stem cells may be positively selected using antibodies specific for CD34, thy-1; or negatively selected using lineage specific markers which may include glycophorin A, CD3, CD24, CD16, CD14, CD38, CD45RA, CD36, CD2, CD19, CD56, CD66a, and CD66b; T cell specific markers, tumor specific markers, *etc.* Markers useful for
15 the separation of mesodermal stem cells include Fc γ RII, Fc γ RIII, Thy-1, CD44, VLA-4 α , LFA-1 β , HSA, ICAM-1, CD45, Aa4.1, Sca-1, *etc.* Neural crest stem cells may be positively selected with antibodies specific for low-affinity nerve growth factor receptor (LNGFR), and negatively selected for the markers sulfatide, glial fibrillary acidic protein (GFAP), myelin protein P₀, peripherin and neurofilament. Human mesenchymal stem cells may be positively
20 separated using the markers SH2, SH3 and SH4.

The cells of interest are typically mammalian, where the term refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, laboratory, sports, or pet animals, such as dogs, horses, cats, cows, mice, rats, rabbits, *etc.* Preferably, the mammal is human.

25 The cells which are employed may be fresh, frozen, or have been subject to prior culture. They may be fetal, neonate, adult. Hematopoietic cells may be obtained from fetal liver, bone marrow, blood, particularly G-CSF or GM-CSF mobilized peripheral blood, or any other conventional source. The manner in which the stem cells are separated from other cells of the hematopoietic or other lineage is not critical to this invention. As described
30 above, a substantially homogeneous population of stem or progenitor cells may be obtained by selective isolation of cells free of markers associated with differentiated cells, while displaying epitopic characteristics associated with the stem cells.

Culture medium: The stem or progenitor cells are grown *in vitro* in an appropriate
35 liquid nutrient medium. Generally, the seeding level will be at least about 10 cells/ml, more usually at least about 100 cells/ml and generally not more than about 10⁵ cells/ml, usually not more than about 10⁴ cells/ml.

Various media are commercially available and may be used, including Ex vivo serum free medium; Dulbecco's Modified Eagle Medium (DMEM), RPMI, Iscove's medium, etc. The medium may be supplemented with serum or with defined additives. Appropriate antibiotics to prevent bacterial growth and other additives, such as pyruvate (0.1-5 mM), glutamine (0.5-5 mM), 2-mercaptoethanol ($1-10 \times 10^{-5}$ M) may also be included.

Culture in serum-free medium is of particular interest. The medium may be any conventional culture medium, generally supplemented with additives such as iron-saturated transferrin, human serum albumin, soy bean lipids, linoleic acid, cholesterol, alpha thioglycerol, crystalline bovine hemin, etc., that allow for the growth of hematopoietic cells.

Preferably the expansion medium is free of cytokines, particularly cytokines that induce cellular differentiation. The term cytokine may include lymphokines, monokines and growth factors. Included among the cytokines are thrombopoietin (TPO); nerve growth factors such as NGF- β ; platelet-growth factor; transforming growth factors (TGFs) such as TGF- α and TGF- β ; erythropoietin (EPO); interferons such as interferon- α , - β , and - γ ; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1 α , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; etc. In some circumstances, proliferative factors that do not induce cellular differentiation may be included in the cultures, e.g. c-kit ligand, LIF, and the like.

EXPANSION OF STEM/PROGENITOR CELLS

A population of cells comprising progenitor and/or stem cells is cultured *in vitro* in the presence of enhanced levels of β -catenin, either by genetically altering the cells, or by providing exogenous β -catenin, as described above. The upregulation in β -catenin is sufficient to maintain or increase the number of assayable progenitor cells in the culture. The number of assayable progenitor cells may be demonstrated by a number of assays. After one week the progenitor cell cloning efficiency will usually be at least about 75% that of the starting cell population, more usually 100% that of the starting cell population, and may be as high as 200% that of the starting cell population.

Following the initial period, there is an increased expansion, where the number of assayable cells having the functional phenotype of the initial cell population can increase from about 5 to about 100 fold or more. After this time, the cells can remain in cycle, and expansion is limited primarily by considerations of space. The cells can be frozen using conventional methods at any time, usually after the first week of culture.

Frequently stem cells are isolated from biological sources in a quiescent state. Certain expression vectors, particularly retroviral vectors, do not effectively infect non-cycling cells. Cultures established with these vectors as a source of beta-catenin sequences are

induced to enter the cell cycle by a short period of time in culture with growth factors. For example, hematopoietic stem cells are induced to divide by culture with c-kit ligand, which may be combined with LIF, IL-11 and thrombopoietin. After 24 to 72 hours in culture with cytokines, the medium is changed, and the cells are contacted with the retroviral culture, using culture conditions as described above.

After seeding the culture medium, the culture medium is maintained under conventional conditions for growth of mammalian cells, generally about 37° C and 5% CO₂ in 100% humidified atmosphere. Fresh media may be conveniently replaced, in part, by removing a portion of the media and replacing it with fresh media. Various commercially available systems have been developed for the growth of mammalian cells to provide for removal of adverse metabolic products, replenishment of nutrients, and maintenance of oxygen. By employing these systems, the medium may be maintained as a continuous medium, so that the concentrations of the various ingredients are maintained relatively constant or within a predescribed range. Such systems can provide for enhanced maintenance and growth of the subject cells using the designated media and additives.

These cells may find various applications for a wide variety of purposes. The cell populations may be used for screening various additives for their effect on growth and the mature differentiation of the cells. In this manner, compounds which are complementary, agonistic, antagonistic or inactive may be screened, determining the effect of the compound in relationship with one or more of the different cytokines.

The populations may be employed as grafts for transplantation. For example, hematopoietic cells are used to treat malignancies, bone marrow failure states and congenital metabolic, immunologic and hematologic disorders. Marrow samples may be taken from patients with cancer, and enriched populations of hematopoietic stem cells isolated by means of density centrifugation, counterflow centrifugal elutriation, monoclonal antibody labeling and fluorescence activated cell sorting. The stem cells in this cell population are then expanded *in vitro* and can serve as a graft for autologous marrow transplantation. The graft will be infused after the patient has received curative chemotherapy.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is

weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

The present invention has been described in terms of particular embodiments found or proposed by the present inventor to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. For example, due to codon redundancy, changes can be made in the underlying DNA sequence without affecting the protein sequence. Moreover, due to biological functional equivalency considerations, changes can be made in protein structure without affecting the biological action in kind or amount. All such modifications are intended to be included within the scope of the appended claims.

EXPERIMENTAL

Bone marrow cells from BCl2 transgenic mice were isolated, enriched for c-kit over a magnetic column, and then stained with antibodies to sort the Sca1⁺ Thy1.1^{lo} c-kit⁺ lin^{-lo} population on a cell sorter. The cells were double sorted to ensure a high level of purity.

The cells were cultured to initiate cell cycle with Steel factor 100ng/ml with 5% serum in X-Vivo 15 containing the retrovirus. At 3 days 50% of media was replaced with only X-vivo 15, and this dilution was repeated every 2 days. The cells were then cultured with supernatant containing retrovirus encoding activated beta-catenin and recombinant steel factor. The increased growth of the stem cells is shown in Figure 1.

The retroviral supernatant had been generated in commercially available X-vivo 15 media using phoenix cells and a MSCV retroviral construct containing beta-catenin driven by the LTR. The retroviral construct is called MSCV and contains an IRES-GFP, in order to label infected cells. The activating beta catenin mutation is a mutation at the amino terminus that prevents phosphorylation and subsequent degradation by proteosomes. The accumulation of beta catenin in the cytosol allows it to translocate to the nucleus where it associates with the LEF/TCF family of transcription factors to turn on gene expression.

50% of the culture supernatant was replaced every day for 3 days. At the end of this culture period the media was replaced with X-vivo 15. Clusters of cells grew out of this culture, and were analyzed at 5 weeks. By May-Gruenwald-Geimsa staining, these cells appeared to have an immature phenotype with large nuclei and small cytoplasm. By FACS staining a majority of cells are Thy1^{lo} Sca-1⁺Lin^{lo}-kit^{lo}, a phenotype resembling that of stem

cells. About 50% of the cells are Lin⁻ (LT-HSC phenotype), and 50% Lin^{lo} (ST-HSC phenotype). The analysis is shown in Figure 2.

These cells give rise to lineage positive cells at 4 weeks when transplanted into lethally irradiated mice suggesting that they are able to differentiate to various lineages *in vivo*, while remaining immature *in vitro*.

Lethally irradiated mice were injected with 300, 000 host bone marrow and 100,000 cultured cells. Peripheral blood was take at a later time, at 2 weeks, 3 weeks and 4 weeks so far. Donor type was marked with Ly5.1+ cells. Level of differentiation was determined by using antibodies to mature lineage markers. The results are shown in Figure 3, demonstrating that stem cells over-expressing β -catenin have the ability to give rise to multiple lineages when transplanted.

WHAT IS CLAIMED IS:

1. A method for *in vitro* expansion of mammalian stem or progenitor cells, the method comprising:

5 increasing the intracellular concentration of β -catenin in a progenitor or stem cell in an *in vitro* culture medium for a period of time sufficient for said progenitor or stem cell to divide;

wherein the number of cells having the functional phenotype of said stem or progenitor cells is expanded.

10 2. The method of Claim 1, wherein said stem or progenitor cell is a stem cell.

3. The method of Claim 2, wherein said stem cell is a hematopoietic stem cell.

4. The method of Claim 2, wherein said stem cell is a neural crest stem cell.

15 5. The method of Claim 2, wherein said stem cell is a mesenchymal stem cell.

6. The method of Claim 2, wherein said stem cell is an embryonic stem cell.

20 7. The method of Claim 3, wherein said hematopoietic stem cell is a human cell.

8. The method of Claim 1, wherein said step of increasing the intracellular concentration of β -catenin comprises:

25 introduction of an exogenous nucleic acid comprising beta-catenin coding sequences operably linked to a promoter.

9. The method of Claim 8, wherein said beta-catenin is a wild-type beta-catenin.

10. The method of Claim 8, wherein said beta-catenin is a stabilized mutant beta-catenin.

30 11. The method of Claim 8, wherein said exogenous nucleic acid is a retroviral vector.

35 12. The method of Claim 11, wherein said retroviral vector comprises sites for recombination, flanking said beta-catenin coding sequences.

13. The method of Claim 8, wherein said exogenous nucleic acid is an episomal vector.

14. The method of Claim 1, wherein said step of increasing the intracellular concentration of β -catenin comprises:
5 addition of exogenous beta-catenin to said culture medium.

15. The method of Claim 14, wherein said beta-catenin is a wild-type beta-catenin.
10

16. The method of Claim 14, wherein said beta-catenin is a stabilized mutant beta-catenin.

17. The method of Claim 14, wherein said beta-catenin is genetically fused to a transport moiety.
15

18. The method of Claim 17, wherein said transport moiety is a fragment of HIV tat protein.

19. The method of Claim 1, wherein said stem or progenitor cell is a progenitor cell.
20

20. The method of Claim 19, wherein said progenitor cell is a hematopoietic progenitor cell.

21. The method of Claim 20, wherein said hematopoietic progenitor cell is a lymphoid cell.
25

22. The method of Claim 21, wherein said lymphoid cell is a B cell.
30

23. The method of Claim 21, wherein said lymphoid cell is a T cell.

1/3




Figure 1

2/3




Figure 2

3/3




Figure 3

SEQUENCE LISTING

<110> Tannishtha Reya
Roeland Nusse
Irving L. Weissman

<120> Use of beta-catenin in the expansion of
stem and progenitor cells

<130> SUN-175WO

<160> 4

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 3362

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (215)...(2560)

<400> 1

aagcctctcg gtctgtggca gcagcggttg cccggccccg ggagcggaga gcgaggggag	60
gcgagacgg aggaaggtct gaggagcagc ttcagtcccc gccgagccgc caccgcaggt	120
cgaggacggt cggactcccc cggcgggagg agcctgttcc cctgagggtta tttgaagtat	180
accatacaac tgttttgaaa atccagcgtg gaca atg gct act caa gct gat ttg	235
Met Ala Thr Gln Ala Asp Leu	
1 5	

atg gag ttg gac atg gcc atg gaa cca gac aga aaa gcg gct gtt agt	283
Met Glu Leu Asp Met Ala Met Glu Pro Asp Arg Lys Ala Ala Val Ser	
10 15 20	

cac tgg cag caa cag tct tac ctg gac tct gga atc cat tct ggt gcc	331
His Trp Gln Gln Gln Ser Tyr Leu Asp Ser Gly Ile His Ser Gly Ala	
25 30 35	

act acc aca gct cct tct ctg agt ggt aaa ggc aat cct gag gaa gag	379
Thr Thr Thr Ala Pro Ser Leu Ser Gly Lys Gly Asn Pro Glu Glu Glu	
40 45 50 55	

gat gtg gat acc tcc caa gtc ctg tat gag tgg gaa cag gga ttt tct	427
Asp Val Asp Thr Ser Gln Val Leu Tyr Glu Trp Glu Gln Gly Phe Ser	
60 65 70	

cag tcc ttc act caa gaa caa gta gct gat att gat gga cag tat gca	475
Gln Ser Phe Thr Gln Glu Gln Val Ala Asp Ile Asp Gly Gln Tyr Ala	
75 80 85	

atg act cga gct cag agg gta cga gct gct atg ttc cct gag aca tta	523
Met Thr Arg Ala Gln Arg Val Arg Ala Ala Met Phe Pro Glu Thr Leu	
90 95 100	

gat gag ggc atg cag atc cca tct aca cag ttt gat gct gct cat ccc	571
Asp Glu Gly Met Gln Ile Pro Ser Thr Gln Phe Asp Ala Ala His Pro	
105 110 115	

act aat gtc cag cgt ttg gct gaa cca tca cag atg ctg aaa cat gca Thr Asn Val Gln Arg Leu Ala Glu Pro Ser Gln Met Leu Lys His Ala 120 125 130 135	619
gtt gta aac ttg att aac tat caa gat gat gca gaa ctt gcc aca cgt Val Val Asn Leu Ile Asn Tyr Gln Asp Asp Ala Glu Leu Ala Thr Arg 140 145 150	667
gca atc cct gaa ctg aca aaa ctg cta aat gac gag gac cag gtg gtg Ala Ile Pro Glu Leu Thr Lys Leu Leu Asn Asp Glu Asp Gln Val Val 155 160 165	715
gtt aat aag gct gca gtt atg gtc cat cag ctt tct aaa aag gaa gct Val Asn Lys Ala Ala Val Met Val His Gln Leu Ser Lys Lys Glu Ala 170 175 180	763
tcc aga cac gct atc atg cgt tct cct cag atg gtg tct gct att gta Ser Arg His Ala Ile Met Arg Ser Pro Gln Met Val Ser Ala Ile Val 185 190 195	811
cgt acc atg cag aat aca aat gat gta gaa aca gct cgt tgt acc gct Arg Thr Met Gln Asn Thr Asn Asp Val Glu Thr Ala Arg Cys Thr Ala 200 205 210 215	859
ggg acc ttg cat aac ctt tcc cat cat cgt gag ggc tta ctg gcc atc Gly Thr Leu His Asn Leu Ser His His Arg Glu Gly Leu Leu Ala Ile 220 225 230	907
ttt aag tct gga ggc att cct gcc ctg gtg aaa atg ctt ggt tca cca Phe Lys Ser Gly Gly Ile Pro Ala Leu Val Lys Met Leu Gly Ser Pro 235 240 245	955
gtg gat tct gtg ttg ttt tat gcc att aca act ctc cac aac ctt tta Val Asp Ser Val Leu Phe Tyr Ala Ile Thr Thr Leu His Asn Leu Leu 250 255 260	1003
tta cat caa gaa gga gct aaa atg gca gtg cgt tta gct ggt ggg ctg Leu His Gln Glu Gly Ala Lys Met Ala Val Arg Leu Ala Gly Gly Leu 265 270 275	1051
cag aaa atg gtt gcc ttg ctc aac aaa aca aat gtt aaa ttc ttg gct Gln Lys Met Val Ala Leu Leu Asn Lys Thr Asn Val Lys Phe Leu Ala 280 285 290 295	1099
att acg aca gac tgc ctt caa att tta gct tat ggc aac caa gaa agc Ile Thr Thr Asp Cys Leu Gln Ile Leu Ala Tyr Gly Asn Gln Glu Ser 300 305 310	1147
aag ctc atc ata ctg gct agt ggt gga ccc caa gct tta gta aat ata Lys Leu Ile Ile Leu Ala Ser Gly Gly Pro Gln Ala Leu Val Asn Ile 315 320 325	1195
atg agg acc tat act tac gaa aaa cta ctg tgg acc aca agc aga gtg Met Arg Thr Tyr Thr Tyr Glu Lys Leu Leu Trp Thr Thr Ser Arg Val 330 335 340	1243
ctg aag gtg cta tct gtc tgc tct agt aat aag ccg gct att gta gaa Leu Lys Val Leu Ser Val Cys Ser Ser Asn Lys Pro Ala Ile Val Glu 345 350 355	1291

gct ggt gga atg caa gct tta gga ctt cac ctg aca gat cca agt caa Ala Gly Gly Met Gln Ala Leu Gly Leu His Leu Thr Asp Pro Ser Gln 360 365 370 375	1339
cgt ctt gtt cag aac tgt ctt tgg act ctc agg aat ctt tca gat gct Arg Leu Val Gln Asn Cys Leu Trp Thr Leu Arg Asn Leu Ser Asp Ala 380 385 390	1387
gca act aaa cag gaa ggg atg gaa ggt ctc ctt ggg act ctt gtt cag Ala Thr Lys Gln Glu Gly Met Glu Gly Leu Leu Gly Thr Leu Val Gln 395 400 405	1435
ctt ctg ggt tca gat gat ata aat gtg gtc acc tgt gca gct gga att Leu Leu Gly Ser Asp Asp Ile Asn Val Val Thr Cys Ala Ala Gly Ile 410 415 420	1483
ctt tct aac ctc act tgc aat aat tat aag aac aag atg atg gtc tgc Leu Ser Asn Leu Thr Cys Asn Asn Tyr Lys Asn Lys Met Met Val Cys 425 430 435	1531
caa gtg ggt ggt ata gag gct ctt gtg cgt act gtc ctt cgg gct ggt Gln Val Gly Gly Ile Glu Ala Leu Val Arg Thr Val Leu Arg Ala Gly 440 445 450 455	1579
gac agg gaa gac atc act gag cct gcc atc tgt gct ctt cgt cat ctg Asp Arg Glu Asp Ile Thr Glu Pro Ala Ile Cys Ala Leu Arg His Leu 460 465 470	1627
acc agc cga cac caa gaa gca gag atg gcc cag aat gca gtt cgc ctt Thr Ser Arg His Gln Glu Ala Glu Met Ala Gln Asn Ala Val Arg Leu 475 480 485	1675
cac tat gga cta cca gtt gtg gtt aag ctc tta cac cca cca tcc cac His Tyr Gly Leu Pro Val Val Val Lys Leu Leu His Pro Pro Ser His 490 495 500	1723
tgg cct ctg ata aag gct act gtt gga ttg att cga aat ctt gcc ctt Trp Pro Leu Ile Lys Ala Thr Val Gly Leu Ile Arg Asn Leu Ala Leu 505 510 515	1771
tgt ccc gca aat cat gca cct ttg cgt gag cag ggt gcc att cca cga Cys Pro Ala Asn His Ala Pro Leu Arg Glu Gln Gly Ala Ile Pro Arg 520 525 530 535	1819
cta gtt cag ttg ctt gtt cgt gca cat cag gat acc cag cgc cgt acg Leu Val Gln Leu Leu Val Arg Ala His Gln Asp Thr Gln Arg Arg Thr 540 545 550	1867
tcc atg ggt ggg aca cag cag caa ttt gtg gag ggg gtc cgc atg gaa Ser Met Gly Gly Thr Gln Gln Gln Phe Val Glu Gly Val Arg Met Glu 555 560 565	1915
gaa ata gtt gaa ggt tgt acc gga gcc ctt cac atc cta gct cgg gat Glu Ile Val Glu Gly Cys Thr Gly Ala Leu His Ile Leu Ala Arg Asp 570 575 580	1963
gtt cac aac cga att gtt atc aga gga cta aat acc att cca ttg ttt Val His Asn Arg Ile Val Ile Arg Gly Leu Asn Thr Ile Pro Leu Phe 585 590 595	2011

gtg	cag	ctg	ctt	tat	tct	ccc	att	gaa	aac	atc	caa	aga	gta	gct	gca	2059
Val	Gln	Leu	Leu	Tyr	Ser	Pro	Ile	Glu	Asn	Ile	Gln	Arg	Val	Ala	Ala	
600					605					610					615	
ggg	gtc	ctc	tgt	gaa	ctt	gct	cag	gac	aag	gaa	gct	gca	gaa	gct	att	2107
Gly	Val	Leu	Cys	Glu	Leu	Ala	Gln	Asp	Lys	Glu	Ala	Ala	Glu	Ala	Ile	
				620					625						630	
gaa	gct	gag	gga	gcc	aca	gct	cct	ctg	aca	gag	tta	ctt	cac	tct	agg	2155
Glu	Ala	Glu	Gly	Ala	Thr	Ala	Pro	Leu	Thr	Glu	Leu	Leu	His	Ser	Arg	
			635					640					645			
aat	gaa	ggt	gtg	gcg	aca	tat	gca	gct	gct	gtt	ttg	ttc	cga	atg	tct	2203
Asn	Glu	Gly	Val	Ala	Thr	Tyr	Ala	Ala	Ala	Val	Leu	Phe	Arg	Met	Ser	
		650					655						660			
gag	gac	aag	cca	caa	gat	tac	aag	aaa	cgg	ctt	tca	gtt	gag	ctg	acc	2251
Glu	Asp	Lys	Pro	Gln	Asp	Tyr	Lys	Lys	Arg	Leu	Ser	Val	Glu	Leu	Thr	
	665					670						675				
agc	tct	ctc	ttc	aga	aca	gag	cca	atg	gct	tgg	aat	gag	act	gct	gat	2299
Ser	Ser	Leu	Phe	Arg	Thr	Glu	Pro	Met	Ala	Trp	Asn	Glu	Thr	Ala	Asp	
680					685					690					695	
ctt	gga	ctt	gat	att	ggt	gcc	cag	gga	gaa	ccc	ctt	gga	tat	cgc	cag	2347
Leu	Gly	Leu	Asp	Ile	Gly	Ala	Gln	Gly	Glu	Pro	Leu	Gly	Tyr	Arg	Gln	
				700					705						710	
gat	gat	cct	agc	tat	cgt	tct	ttt	cac	tct	ggt	gga	tat	ggc	cag	gat	2395
Asp	Asp	Pro	Ser	Tyr	Arg	Ser	Phe	His	Ser	Gly	Gly	Tyr	Gly	Gln	Asp	
			715					720					725			
gcc	ttg	ggt	atg	gac	ccc	atg	atg	gaa	cat	gag	atg	ggt	ggc	cac	cac	2443
Ala	Leu	Gly	Met	Asp	Pro	Met	Met	Glu	His	Glu	Met	Gly	Gly	His	His	
		730					735					740				
cct	ggt	gct	gac	tat	cca	gtt	gat	ggg	ctg	cca	gat	ctg	ggg	cat	gcc	2491
Pro	Gly	Ala	Asp	Tyr	Pro	Val	Asp	Gly	Leu	Pro	Asp	Leu	Gly	His	Ala	
		745				750					755					
cag	gac	ctc	atg	gat	ggg	ctg	cct	cca	ggt	gac	agc	aat	cag	ctg	gcc	2539
Gln	Asp	Leu	Met	Asp	Gly	Leu	Pro	Pro	Gly	Asp	Ser	Asn	Gln	Leu	Ala	
760					765				770						775	
tgg	ttt	gat	act	gac	ctg	taa	atcatccttt	agctgtattg	tctgaacttg							2590
Trp	Phe	Asp	Thr	Asp	Leu	*										
					780											
cattgtgatt	ggcctgtaga	gttgctgaga	gggctcgagg	ggtgggctgg	tatctcagaa											2650
agtgcctgac	acactaacca	agctgagttt	cctatgggaa	caattgaagt	aaactttttg											2710
ttctggtcct	ttttggtcga	ggagtaacaa	tacaaatgga	ttttgggagt	gactcaagaa											2770
gtgaagaatg	cacaagaatg	gatcacaaga	tggaatttag	caaaccctag	ccttgcttgt											2830
taaaattttt	tttttttttt	ttttaagaat	atctgtaatg	gtactgactt	tgcttgcttt											2890
gaagtagctc	tttttttttt	tttttttttt	tttttttgca	gtaactgttt	tttaagtctc											2950
tcgtagtggt	aagttatagt	gaatactgct	acagcaattt	ctaattttta	agaattgagt											3010
aatggtgtag	aacactaatt	aattcataat	cactctaatt	aattgtaatc	tgaataaagt											3070
gtaacaattg	tgtagccttt	ttgtataaaa	tagacaaata	gaaaatgggc	caattagttt											3130
cctttttaat	atgcttaaaa	taagcagggtg	gatctatttc	atgtttttga	tcaaaaacta											3190
tttgggatat	gtatgggtag	ggtaaatacag	taagaggtgt	tatttggaac	cttgtttttg											3250

acagttttacc agttgccttt tatcccaaag ttgttgtaac ctgctgtgat acgatgcttc 3310
 aagagaaaaat gcggttataa aaaatgggtc agaattaaac ttttaattca tt 3362

<210> 2
 <211> 781
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Ala Thr Gln Ala Asp Leu Met Glu Leu Asp Met Ala Met Glu Pro
 1 5 10 15
 Asp Arg Lys Ala Ala Val Ser His Trp Gln Gln Gln Ser Tyr Leu Asp
 20 25 30
 Ser Gly Ile His Ser Gly Ala Thr Thr Thr Ala Pro Ser Leu Ser Gly
 35 40 45
 Lys Gly Asn Pro Glu Glu Glu Asp Val Asp Thr Ser Gln Val Leu Tyr
 50 55 60
 Glu Trp Glu Gln Gly Phe Ser Gln Ser Phe Thr Gln Glu Gln Val Ala
 65 70 75 80
 Asp Ile Asp Gly Gln Tyr Ala Met Thr Arg Ala Gln Arg Val Arg Ala
 85 90 95
 Ala Met Phe Pro Glu Thr Leu Asp Glu Gly Met Gln Ile Pro Ser Thr
 100 105 110
 Gln Phe Asp Ala Ala His Pro Thr Asn Val Gln Arg Leu Ala Glu Pro
 115 120 125
 Ser Gln Met Leu Lys His Ala Val Val Asn Leu Ile Asn Tyr Gln Asp
 130 135 140
 Asp Ala Glu Leu Ala Thr Arg Ala Ile Pro Glu Leu Thr Lys Leu Leu
 145 150 155 160
 Asn Asp Glu Asp Gln Val Val Val Asn Lys Ala Ala Val Met Val His
 165 170 175
 Gln Leu Ser Lys Lys Glu Ala Ser Arg His Ala Ile Met Arg Ser Pro
 180 185 190
 Gln Met Val Ser Ala Ile Val Arg Thr Met Gln Asn Thr Asn Asp Val
 195 200 205
 Glu Thr Ala Arg Cys Thr Ala Gly Thr Leu His Asn Leu Ser His His
 210 215 220
 Arg Glu Gly Leu Leu Ala Ile Phe Lys Ser Gly Gly Ile Pro Ala Leu
 225 230 235 240
 Val Lys Met Leu Gly Ser Pro Val Asp Ser Val Leu Phe Tyr Ala Ile
 245 250 255
 Thr Thr Leu His Asn Leu Leu Leu His Gln Glu Gly Ala Lys Met Ala
 260 265 270
 Val Arg Leu Ala Gly Gly Leu Gln Lys Met Val Ala Leu Leu Asn Lys
 275 280 285
 Thr Asn Val Lys Phe Leu Ala Ile Thr Thr Asp Cys Leu Gln Ile Leu
 290 295 300
 Ala Tyr Gly Asn Gln Glu Ser Lys Leu Ile Ile Leu Ala Ser Gly Gly
 305 310 315 320
 Pro Gln Ala Leu Val Asn Ile Met Arg Thr Tyr Thr Tyr Glu Lys Leu
 325 330 335
 Leu Trp Thr Thr Ser Arg Val Leu Lys Val Leu Ser Val Cys Ser Ser
 340 345 350
 Asn Lys Pro Ala Ile Val Glu Ala Gly Gly Met Gln Ala Leu Gly Leu
 355 360 365
 His Leu Thr Asp Pro Ser Gln Arg Leu Val Gln Asn Cys Leu Trp Thr
 370 375 380
 Leu Arg Asn Leu Ser Asp Ala Ala Thr Lys Gln Glu Gly Met Glu Gly
 385 390 395 400

Leu Leu Gly Thr Leu Val Gln Leu Leu Gly Ser Asp Asp Ile Asn Val
 405 410 415
 Val Thr Cys Ala Ala Gly Ile Leu Ser Asn Leu Thr Cys Asn Asn Tyr
 420 425 430
 Lys Asn Lys Met Met Val Cys Gln Val Gly Gly Ile Glu Ala Leu Val
 435 440 445
 Arg Thr Val Leu Arg Ala Gly Asp Arg Glu Asp Ile Thr Glu Pro Ala
 450 455 460
 Ile Cys Ala Leu Arg His Leu Thr Ser Arg His Gln Glu Ala Glu Met
 465 470 475 480
 Ala Gln Asn Ala Val Arg Leu His Tyr Gly Leu Pro Val Val Val Lys
 485 490 495
 Leu Leu His Pro Pro Ser His Trp Pro Leu Ile Lys Ala Thr Val Gly
 500 505 510
 Leu Ile Arg Asn Leu Ala Leu Cys Pro Ala Asn His Ala Pro Leu Arg
 515 520 525
 Glu Gln Gly Ala Ile Pro Arg Leu Val Gln Leu Leu Val Arg Ala His
 530 535 540
 Gln Asp Thr Gln Arg Arg Thr Ser Met Gly Gly Thr Gln Gln Gln Phe
 545 550 555 560
 Val Glu Gly Val Arg Met Glu Glu Ile Val Glu Gly Cys Thr Gly Ala
 565 570 575
 Leu His Ile Leu Ala Arg Asp Val His Asn Arg Ile Val Ile Arg Gly
 580 585 590
 Leu Asn Thr Ile Pro Leu Phe Val Gln Leu Leu Tyr Ser Pro Ile Glu
 595 600 605
 Asn Ile Gln Arg Val Ala Ala Gly Val Leu Cys Glu Leu Ala Gln Asp
 610 615 620
 Lys Glu Ala Ala Glu Ala Ile Glu Ala Glu Gly Ala Thr Ala Pro Leu
 625 630 635 640
 Thr Glu Leu Leu His Ser Arg Asn Glu Gly Val Ala Thr Tyr Ala Ala
 645 650 655
 Ala Val Leu Phe Arg Met Ser Glu Asp Lys Pro Gln Asp Tyr Lys Lys
 660 665 670
 Arg Leu Ser Val Glu Leu Thr Ser Ser Leu Phe Arg Thr Glu Pro Met
 675 680 685
 Ala Trp Asn Glu Thr Ala Asp Leu Gly Leu Asp Ile Gly Ala Gln Gly
 690 695 700
 Glu Pro Leu Gly Tyr Arg Gln Asp Asp Pro Ser Tyr Arg Ser Phe His
 705 710 715 720
 Ser Gly Gly Tyr Gly Gln Asp Ala Leu Gly Met Asp Pro Met Met Glu
 725 730 735
 His Glu Met Gly Gly His His Pro Gly Ala Asp Tyr Pro Val Asp Gly
 740 745 750
 Leu Pro Asp Leu Gly His Ala Gln Asp Leu Met Asp Gly Leu Pro Pro
 755 760 765
 Gly Asp Ser Asn Gln Leu Ala Trp Phe Asp Thr Asp Leu
 770 775 780

<210> 3

<211> 2702

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (98)... (2443)

<400> 3

gaattccgag cgtcagtgca ggaggccgat tccgagcggg cggccgcgag gtaggtgaag	60
ctcagcgcag agctgctgtg acaccgctgc gtggaca atg gct act caa gct gac	115
Met Ala Thr Gln Ala Asp	
1 5	
ctg atg gag ttg gac atg gcc atg gag ccg gac aga aaa gct gct gtc	163
Leu Met Glu Leu Asp Met Ala Met Glu Pro Asp Arg Lys Ala Ala Val	
10 15 20	
agc cac tgg cag cag cag tct tac ttg gat tct gga atc cat tct ggt	211
Ser His Trp Gln Gln Gln Ser Tyr Leu Asp Ser Gly Ile His Ser Gly	
25 30 35	
gcc acc acc aca gct cct tcc ctg agt ggc aag ggc aac cct gag gaa	259
Ala Thr Thr Thr Ala Pro Ser Leu Ser Gly Lys Gly Asn Pro Glu Glu	
40 45 50	
gaa gat gtt gac acc tcc caa gtc ctt tat gaa tgg gag caa ggc ttt	307
Glu Asp Val Asp Thr Ser Gln Val Leu Tyr Glu Trp Glu Gln Gly Phe	
55 60 65 70	
tcc cag tcc ttc acg caa gag caa gta gct gat att gac ggg cag tat	355
Ser Gln Ser Phe Thr Gln Glu Gln Val Ala Asp Ile Asp Gly Gln Tyr	
75 80 85	
gca atg act agg gct cag agg gtc cga gct gcc atg ttc cct gag acg	403
Ala Met Thr Arg Ala Gln Arg Val Arg Ala Ala Met Phe Pro Glu Thr	
90 95 100	
cta gat gag ggc atg cag atc cca tcc acg cag ttt gac gct gct cat	451
Leu Asp Glu Gly Met Gln Ile Pro Ser Thr Gln Phe Asp Ala Ala His	
105 110 115	
ccc act aat gtc cag cgc ttg gct gaa cca tca cag atg ttg aaa cat	499
Pro Thr Asn Val Gln Arg Leu Ala Glu Pro Ser Gln Met Leu Lys His	
120 125 130	
gca gtt gtc aat ttg att aac tat cag gat gac gcg gaa ctt gcc aca	547
Ala Val Val Asn Leu Ile Asn Tyr Gln Asp Asp Ala Glu Leu Ala Thr	
135 140 145 150	
cgt gca att cct gag ctg aca aaa ctg cta aac gat gag gac cag gtg	595
Arg Ala Ile Pro Glu Leu Thr Lys Leu Leu Asn Asp Glu Asp Gln Val	
155 160 165	
gta gtt aat aaa gct gct gtt atg gtc cat cag ctt tcc aaa aag gaa	643
Val Val Asn Lys Ala Ala Val Met Val His Gln Leu Ser Lys Lys Glu	
170 175 180	
gct tcc aga cat gcc atc atg cgc tcc cct cag atg gtg tct gcc att	691
Ala Ser Arg His Ala Ile Met Arg Ser Pro Gln Met Val Ser Ala Ile	
185 190 195	
gta cgc acc atg cag aat aca aat gat gta gag aca gct cgt tgt act	739
Val Arg Thr Met Gln Asn Thr Asn Asp Val Glu Thr Ala Arg Cys Thr	
200 205 210	
gct ggg acc ctt cac aac ctt tct cac cac cgc gag ggc ttg ctg gcc	787
Ala Gly Thr Leu His Asn Leu Ser His His Arg Glu Gly Leu Leu Ala	
215 220 225 230	

atc ttt aag tct ggt ggc atc cca gcg ctg gtg aaa atg ctt ggg tca Ile Phe Lys Ser Gly Gly Ile Pro Ala Leu Val Lys Met Leu Gly Ser 235 240 245	835
cca gtg gat tct gta ctg ttc tac gcc atc acg aca ctg cat aat ctc Pro Val Asp Ser Val Leu Phe Tyr Ala Ile Thr Thr Leu His Asn Leu 250 255 260	883
ctg ctc cat cag gaa gga gct aaa atg gca gtg cgc cta gct ggt gga Leu Leu His Gln Glu Gly Ala Lys Met Ala Val Arg Leu Ala Gly Gly 265 270 275	931
ctg cag aaa atg gtt gct ttg ctc aac aaa aca aac gtg aaa ttc ttg Leu Gln Lys Met Val Ala Leu Leu Asn Lys Thr Asn Val Lys Phe Leu 280 285 290	979
gct att aca aca gac tgc ctt cag atc tta gct tat ggc aat caa gag Ala Ile Thr Thr Asp Cys Leu Gln Ile Leu Ala Tyr Gly Asn Gln Glu 295 300 305 310	1027
agc aag ctc atc att ctg gcc agt ggt gga ccc caa gcc tta gta aac Ser Lys Leu Ile Ile Leu Ala Ser Gly Gly Pro Gln Ala Leu Val Asn 315 320 325	1075
ata atg agg acc tac act tat gag aag ctt ctg tgg acc aca agc aga Ile Met Arg Thr Tyr Thr Tyr Glu Lys Leu Leu Trp Thr Thr Ser Arg 330 335 340	1123
gtg ctg aaa gtg ctg tct gtc tgc tct agc aac aag ccg gcc att gta Val Leu Lys Val Leu Ser Val Cys Ser Ser Asn Lys Pro Ala Ile Val 345 350 355	1171
gaa gct ggt ggg atg cag gca ctg ggg ctt cat ctg aca gac cca agt Glu Ala Gly Gly Met Gln Ala Leu Gly Leu His Leu Thr Asp Pro Ser 360 365 370	1219
cag cga ctt gtt caa aac tgt ctt tgg act ctc aga aac ctt tca gat Gln Arg Leu Val Gln Asn Cys Leu Trp Thr Leu Arg Asn Leu Ser Asp 375 380 385 390	1267
gca gcg act aag cag gaa ggg atg gaa ggc ctc ctt ggg act cta gtg Ala Ala Thr Lys Gln Glu Gly Met Glu Gly Leu Leu Gly Thr Leu Val 395 400 405	1315
cag ctt ctg ggt tcc gat gat ata aat gtg gtc acc tgt gca gct gga Gln Leu Leu Gly Ser Asp Asp Ile Asn Val Val Thr Cys Ala Ala Gly 410 415 420	1363
att ctc tct aac ctc act tgc aat aat tac aaa aac aag atg atg gtg Ile Leu Ser Asn Leu Thr Cys Asn Asn Tyr Lys Asn Lys Met Met Val 425 430 435	1411
tgc caa gtg ggt ggc ata gag gct ctt gta cgc acc gtc ctt cgt gct Cys Gln Val Gly Gly Ile Glu Ala Leu Val Arg Thr Val Leu Arg Ala 440 445 450	1459
ggt gac agg gaa gac atc act gag cct gcc atc tgt gct ctt cgt cat Gly Asp Arg Glu Asp Ile Thr Glu Pro Ala Ile Cys Ala Leu Arg His 455 460 465 470	1507

ctg acc agc cgg cat cag gaa gcc gag atg gcc cag aat gcc gtt cgc Leu Thr Ser Arg His Gln Glu Ala Glu Met Ala Gln Asn Ala Val Arg 475 480 485	1555
ctt cat tat gga ctg cct gtt gtg gtt aaa ctc ctg cac cca cca tcc Leu His Tyr Gly Leu Pro Val Val Val Lys Leu Leu His Pro Pro Ser 490 495 500	1603
cac tgg cct ctg ata aag gca act gtt gga ttg att cga aac ctt gcc His Trp Pro Leu Ile Lys Ala Thr Val Gly Leu Ile Arg Asn Leu Ala 505 510 515	1651
ctt tgc cca gca aat cat gcg cct ttg cgg gaa cag ggt gct att cca Leu Cys Pro Ala Asn His Ala Pro Leu Arg Glu Gln Gly Ala Ile Pro 520 525 530	1699
cga cta gtt cag ctg ctt gta cga gca cat cag gac acc caa cgg cgc Arg Leu Val Gln Leu Leu Val Arg Ala His Gln Asp Thr Gln Arg Arg 535 540 545 550	1747
acc tcc atg ggt gga acg cag cag cag ttt gtg gag ggc gtg cgc atg Thr Ser Met Gly Gly Thr Gln Gln Gln Phe Val Glu Gly Val Arg Met 555 560 565	1795
gag gaa ata gtc gaa ggg tgt act gga gct ctc cac atc ctt gct cgg Glu Glu Ile Val Glu Gly Cys Thr Gly Ala Leu His Ile Leu Ala Arg 570 575 580	1843
gac gtt cac aac cgg att gta atc cga gga ctc aat acc att cca ttg Asp Val His Asn Arg Ile Val Ile Arg Gly Leu Asn Thr Ile Pro Leu 585 590 595	1891
ttt gtg cag ttg ctt tat tct ccc att gaa aat atc caa aga gta gct Phe Val Gln Leu Leu Tyr Ser Pro Ile Glu Asn Ile Gln Arg Val Ala 600 605 610	1939
gca ggg gtc ctc tgt gaa ctt gct cag gac aag gag gct gca gag gcc Ala Gly Val Leu Cys Glu Leu Ala Gln Asp Lys Glu Ala Ala Glu Ala 615 620 625 630	1987
att gaa gct gag gga gcc aca gct ccc ctg aca gag tta ctc cac tcc Ile Glu Ala Glu Gly Ala Thr Ala Pro Leu Thr Glu Leu Leu His Ser 635 640 645	2035
agg aat gaa ggc gtg gca aca tac gca gct gct gtc cta ttc cga atg Arg Asn Glu Gly Val Ala Thr Tyr Ala Ala Val Leu Phe Arg Met 650 655 660	2083
tct gag gac aag cca cag gat tac aag aag cgg ctt tca gtc gag ctg Ser Glu Asp Lys Pro Gln Asp Tyr Lys Lys Arg Leu Ser Val Glu Leu 665 670 675	2131
acc agt tcc ctc ttc agg aca gag cca atg gct tgg aat gag act gca Thr Ser Ser Leu Phe Arg Thr Glu Pro Met Ala Trp Asn Glu Thr Ala 680 685 690	2179
gat ctt gga ctg gac att ggt gcc cag gga gaa gcc ctt gga tat cgc Asp Leu Gly Leu Asp Ile Gly Ala Gln Gly Glu Ala Leu Gly Tyr Arg 695 700 705 710	2227

cag gat gat ccc agc tac cgt tct ttt cac tct ggt gga tac ggc cag 2275
Gln Asp Asp Pro Ser Tyr Arg Ser Phe His Ser Gly Gly Tyr Gly Gln
715 720 725

gat gcc ttg ggg atg gac cct atg atg gag cat gag atg ggt ggc cac 2323
Asp Ala Leu Gly Met Asp Pro Met Met Glu His Glu Met Gly Gly His
730 735 740

cac cct ggt gct gac tat cca gtt gat ggg ctg cct gat ctg gga cac 2371
His Pro Gly Ala Asp Tyr Pro Val Asp Gly Leu Pro Asp Leu Gly His
745 750 755

gcc cag gac ctc atg gat ggg ctg ccc cca ggt gat agc aat cag ctg 2419
Ala Gln Asp Leu Met Asp Gly Leu Pro Pro Gly Asp Ser Asn Gln Leu
760 765 770

gcc tgg ttt gat act gac ctg taa atcgtcctta gtaagaaagc ttataaaagc 2473
Ala Trp Phe Asp Thr Asp Leu *
775 780

cagtgtgggt gaatacttac tctgcctgca gaactccaga aagacttggt aggggtgggaa 2533
tggttttagg cctgtttgta aatctgccac caaacagata cataccttgg aaggagatgt 2593
tcatgtgtgg aagtttctca cggtgatgtt tttgccacag cttttgcagc gttatactca 2653
gatgagtaac atttgctgtt ttcaacatta atagcagcct tctctctat 2702

<210> 4

<211> 781

<212> PRT

<213> Mus musculus

<400> 4

Met Ala Thr Gln Ala Asp Leu Met Glu Leu Asp Met Ala Met Glu Pro
1 5 10 15
Asp Arg Lys Ala Ala Val Ser His Trp Gln Gln Gln Ser Tyr Leu Asp
20 25 30
Ser Gly Ile His Ser Gly Ala Thr Thr Thr Ala Pro Ser Leu Ser Gly
35 40 45
Lys Gly Asn Pro Glu Glu Glu Asp Val Asp Thr Ser Gln Val Leu Tyr
50 55 60
Glu Trp Glu Gln Gly Phe Ser Gln Ser Phe Thr Gln Glu Gln Val Ala
65 70 75 80
Asp Ile Asp Gly Gln Tyr Ala Met Thr Arg Ala Gln Arg Val Arg Ala
85 90 95
Ala Met Phe Pro Glu Thr Leu Asp Glu Gly Met Gln Ile Pro Ser Thr
100 105 110
Gln Phe Asp Ala Ala His Pro Thr Asn Val Gln Arg Leu Ala Glu Pro
115 120 125
Ser Gln Met Leu Lys His Ala Val Val Asn Leu Ile Asn Tyr Gln Asp
130 135 140
Asp Ala Glu Leu Ala Thr Arg Ala Ile Pro Glu Leu Thr Lys Leu Leu
145 150 155 160
Asn Asp Glu Asp Gln Val Val Val Asn Lys Ala Ala Val Met Val His
165 170 175
Gln Leu Ser Lys Lys Glu Ala Ser Arg His Ala Ile Met Arg Ser Pro
180 185 190
Gln Met Val Ser Ala Ile Val Arg Thr Met Gln Asn Thr Asn Asp Val
195 200 205
Glu Thr Ala Arg Cys Thr Ala Gly Thr Leu His Asn Leu Ser His His
210 215 220

Arg	Glu	Gly	Leu	Leu	Ala	Ile	Phe	Lys	Ser	Gly	Gly	Ile	Pro	Ala	Leu	225	230	235	240
Val	Lys	Met	Leu	Gly	Ser	Pro	Val	Asp	Ser	Val	Leu	Phe	Tyr	Ala	Ile	245	250	255	
Thr	Thr	Leu	His	Asn	Leu	Leu	Leu	His	Gln	Glu	Gly	Ala	Lys	Met	Ala	260	265	270	
Val	Arg	Leu	Ala	Gly	Gly	Leu	Gln	Lys	Met	Val	Ala	Leu	Leu	Asn	Lys	275	280	285	
Thr	Asn	Val	Lys	Phe	Leu	Ala	Ile	Thr	Thr	Asp	Cys	Leu	Gln	Ile	Leu	290	295	300	
Ala	Tyr	Gly	Asn	Gln	Glu	Ser	Lys	Leu	Ile	Ile	Leu	Ala	Ser	Gly	Gly	305	310	315	320
Pro	Gln	Ala	Leu	Val	Asn	Ile	Met	Arg	Thr	Tyr	Thr	Tyr	Glu	Lys	Leu	325	330	335	
Leu	Trp	Thr	Thr	Ser	Arg	Val	Leu	Lys	Val	Leu	Ser	Val	Cys	Ser	Ser	340	345	350	
Asn	Lys	Pro	Ala	Ile	Val	Glu	Ala	Gly	Gly	Met	Gln	Ala	Leu	Gly	Leu	355	360	365	
His	Leu	Thr	Asp	Pro	Ser	Gln	Arg	Leu	Val	Gln	Asn	Cys	Leu	Trp	Thr	370	375	380	
Leu	Arg	Asn	Leu	Ser	Asp	Ala	Ala	Thr	Lys	Gln	Glu	Gly	Met	Glu	Gly	385	390	395	400
Leu	Leu	Gly	Thr	Leu	Val	Gln	Leu	Leu	Gly	Ser	Asp	Asp	Ile	Asn	Val	405	410	415	
Val	Thr	Cys	Ala	Gly	Ile	Leu	Ser	Asn	Leu	Thr	Cys	Asn	Asn	Tyr		420	425	430	
Lys	Asn	Lys	Met	Met	Val	Cys	Gln	Val	Gly	Gly	Ile	Glu	Ala	Leu	Val	435	440	445	
Arg	Thr	Val	Leu	Arg	Ala	Gly	Asp	Arg	Glu	Asp	Ile	Thr	Glu	Pro	Ala	450	455	460	
Ile	Cys	Ala	Leu	Arg	His	Leu	Thr	Ser	Arg	His	Gln	Glu	Ala	Glu	Met	465	470	475	480
Ala	Gln	Asn	Ala	Val	Arg	Leu	His	Tyr	Gly	Leu	Pro	Val	Val	Val	Lys	485	490	495	
Leu	Leu	His	Pro	Pro	Ser	His	Trp	Pro	Leu	Ile	Lys	Ala	Thr	Val	Gly	500	505	510	
Leu	Ile	Arg	Asn	Leu	Ala	Leu	Cys	Pro	Ala	Asn	His	Ala	Pro	Leu	Arg	515	520	525	
Glu	Gln	Gly	Ala	Ile	Pro	Arg	Leu	Val	Gln	Leu	Leu	Val	Arg	Ala	His	530	535	540	
Gln	Asp	Thr	Gln	Arg	Arg	Thr	Ser	Met	Gly	Gly	Thr	Gln	Gln	Gln	Phe	545	550	555	560
Val	Glu	Gly	Val	Arg	Met	Glu	Glu	Ile	Val	Glu	Gly	Cys	Thr	Gly	Ala	565	570	575	
Leu	His	Ile	Leu	Ala	Arg	Asp	Val	His	Asn	Arg	Ile	Val	Ile	Arg	Gly	580	585	590	
Leu	Asn	Thr	Ile	Pro	Leu	Phe	Val	Gln	Leu	Leu	Tyr	Ser	Pro	Ile	Glu	595	600	605	
Asn	Ile	Gln	Arg	Val	Ala	Ala	Gly	Val	Leu	Cys	Glu	Leu	Ala	Gln	Asp	610	615	620	
Lys	Glu	Ala	Ala	Glu	Ala	Ile	Glu	Ala	Glu	Gly	Ala	Thr	Ala	Pro	Leu	625	630	635	640
Thr	Glu	Leu	Leu	His	Ser	Arg	Asn	Glu	Gly	Val	Ala	Thr	Tyr	Ala	Ala	645	650	655	
Ala	Val	Leu	Phe	Arg	Met	Ser	Glu	Asp	Lys	Pro	Gln	Asp	Tyr	Lys	Lys	660	665	670	
Arg	Leu	Ser	Val	Glu	Leu	Thr	Ser	Ser	Leu	Phe	Arg	Thr	Glu	Pro	Met	675	680	685	
Ala	Trp	Asn	Glu	Thr	Ala	Asp	Leu	Gly	Leu	Asp	Ile	Gly	Ala	Gln	Gly	690	695	700	

Glu	Ala	Leu	Gly	Tyr	Arg	Gln	Asp	Asp	Pro	Ser	Tyr	Arg	Ser	Phe	His
705					710					715					720
Ser	Gly	Gly	Tyr	Gly	Gln	Asp	Ala	Leu	Gly	Met	Asp	Pro	Met	Met	Glu
				725					730						735
His	Glu	Met	Gly	Gly	His	His	Pro	Gly	Ala	Asp	Tyr	Pro	Val	Asp	Gly
			740					745					750		
Leu	Pro	Asp	Leu	Gly	His	Ala	Gln	Asp	Leu	Met	Asp	Gly	Leu	Pro	Pro
		755					760					765			
Gly	Asp	Ser	Asn	Gln	Leu	Ala	Trp	Phe	Asp	Thr	Asp	Leu			
770						775					780				

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01459

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 1/02; C12N 5/00, 5/02, 7/00, 15/63, 15/86; C12P 21/04, 21/06
US CL : 435/2, 69.1, 70.1, 455, 235.1, 325, 375, 377

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/2, 69.1, 70.1, 455, 235.1, 325, 375, 377

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
MEDLINE, EAST, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DAMALAS et al. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J. 1999, Vol 18, No. 11, pages 3054-3063, see entire document.	1, 8-9, 11-12
Y	CHU et al. Retrovirus-mediated gene transfer into human hematopoietic stem cells. J. Mol. Med. 1998, Vol 76, pages 184-192, see entire document.	1-3, 7-8, 11-12, 19-20
Y	ZARRIN et al. Comparison of CMV, RSV, SV40 viral and V-lambda-1 cellular promoters in B and T lymphoid and non-lymphoid cell lines. Biochimica et Biophysica Acta 1999, Vol. 1446, pages 135-139, see entire document and Figure 2.	1, 19-23
Y	MORIN et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, Vol. 275, pages 1787-1790, especially page 1789.	9-10
Y	SATOH et al. Successful transfer of ADA gene in vitro into human peripheral blood CD34 positive cells by transfecting EBV-based episomal vectors. FEBS Letters 1998, Vol 441, No.1, pages 39-42, see entire document.	1, 8, 13, 19-23
A	FAGOTTO et al. Cell contact-dependent signaling. Dev. Biol. 1996, Vol 180, pages 445-454, especially pages 449 and 451.	1-3, 7-13, 19-23
A	WILLERT et al. Beta-catenin: a key mediator of Wnt signaling. Curr. Biol. 1998, Vol 8, pages 95-102, see entire document.	1-3, 7-13, 19-23



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

04 April 2001 (04.04.2001)

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Date of mailing of the international search report

27 APR 2001

Authorized officer

Bridget E. Bunner

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/Us01/01459

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZIEGLER et al. Expansion of stem and progenitor cells. Curr. Opin. Hematol. 1998, Vol 5, pages 434-440, see entire document.	1-3, 7-13, 19-23
A	US 5,851,984A (MATTHEWS et al) 22 December 1998 (22.12.1998), see entire document.	1-3, 7-13, 19-23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01459

Continuation of Item 4 of the first sheet: The current title is too long under PCT Rule 4.3. The new title suggestion: "Expansion of Stem and Progenitor Cells by beta-catenin".

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-13 and 19-23, in part, drawn to a method for *in vitro* expansion of mammalian stem or progenitor cells comprising increasing intracellular concentration of β -catenin by introduction of an exogenous nucleic acid comprising β -catenin coding sequences.

Group II, claim(s) 1-7 and 14-23, in part, drawn to a method for *in vitro* expansion of mammalian stem or progenitor cells comprising increasing intracellular concentration of β -catenin by addition of exogenous β -catenin.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I-II claim different methods. Group I recites the special technical feature of *in vitro* expansion of stem or progenitor cells comprising introduction of an exogenous beta-catenin nucleic acid molecule which is not required by the method of Groups II. Group II recites the special technical feature of *in vitro* expansion of stem or progenitor cells comprising introduction of an exogenous beta-catenin protein which is not required by the method of Group I.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

- A. hematopoietic stem cell
- B. neural crest stem cell
- C. mesenchymal stem cell
- D. embryonic stem cell

The following claim(s) are generic: 8-23.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The special technical feature of (A) is a hematopoietic stem cell population. This special technical feature is not shared by any of the other species.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In order for more than one species to be examined, the appropriate additional examination fees must be paid. The species are as follows:

- E. wild-type beta-catenin
- F. stabilized mutant beta-catenin

The following claim(s) are generic: 2-7, 11-13, and 17-23.

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The special technical feature of (E) is an isolated beta catenin protein that has not been mutated. This special technical feature is not shared by any of the other species.